AI
Friday, February 03, 2017 11:23:16 AM
MannKind just needs to be able to stay in the race. It's hard when you need more capital to fund the marketing effort. While management intends to try and go it alone they probably be better off selling to the company to a partner who can really commercialize the product.
We know the product is truly a game changer for diabetic treatment. Its not getting positioned for formulary additions to plans as illustrated below.
With a short(four days) week last week scripts were up a bit.
Rx for week ending 1/27/17
NRx 146
TRx 267
TRx $ 196,000
MannKind begins sales training for the newly hired and existing reps next week February 6 - 10, 2017 I guess only time will tell if we can move forward.
We just have to hope the company can follow their what to expect in 2017 slide as presented at JPM in January 2017.
Recent MNKD News
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
